OR WAIT 15 SECS
Oxford Gene Technology (OGT) has revealed it is expanding its operations with a new facility in Cambridge, UK, to house its expanding Cytocell brand.
Provider of genetic research solutions, Oxford Gene Technology (OGT), has revealed it is expanding its operations with a new facility in Cambridge, United Kingdom, to house its expanding Cytocell brand.
Cytocell is OGT’s fluorescence in situ hybridization (FISH) probe brand, the direct sales of which have reportedly been expanding in Europe and Asia. As a result of current sales and anticipate growth, Sysmex-OGT’s parent company-has invested in the new Cambridge facility, expanding Cytocell’s operational footprint.
“We’re delighted to announce the investment in, and expansion of, our Cytocell operations by Sysmex,” said John Anson, CEO of OGT in a Feb. 26, 2019 press release. “Sysmex is committed to growing our business and aligning our commercial synergies. In addition, Sysmex is demonstrating its confidence in the UK’s strong traditional base in life sciences. Our ever-growing cooperation with Sysmex delivers the benefits of being part of a larger organization to our customers, providing them with enhanced services and support.”
The company has reported that the new facility will have three times the floor space of the current premises and there are plans to create a training and demonstration facility within the new site to host customers. Furthermore, Sysmex is considering the creation of a global R&D facility at the Cambridge site dedicated to evaluating new technologies and pursuing collaborations with key opinion leaders with the aim of delivering new products to the market.
Kenji Tsujimoto, executive vice-president of Technology Strategy at Sysmex added, “Our acquisition of OGT has been, and continues to be, extremely successful. This significant investment in the company is testament to our confidence and desire to further develop OGT’s brands alongside our portfolios.”
The Cambridge facility is expected to be fully operational by May 2019.